Psy84 - Impact of High Discontinuation Rates for Secukinumab on Average Costs and Cost-Effectiveness Relative to Other Biological Treatments of Moderate-To-Severe Plaque Psoriasis in Sweden

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2659
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV